Inspiremd presents positive 30-day follow-up results from the c-guardians u.s. investigational device exemption (ide) clinical trial at viva23

Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure

NSPR Ratings Summary

NSPR Quant Ranking